June 15, 2021
1 min read

‘AstraZeneca jab authorised for all age-groups’

The EU has also authorised Pfizer-BioNTech and Moderna’s mRNA based Covid-19 vaccines…reports Asian Lite News.

AstraZeneca’s Covid-19 vaccine remains authorised for all populations, European Medicines Agency (EMA) has said.

The clarification camme after Italian newspaper La Stampa earlier quoted Marco Cavaleri, head of the EMA’s vaccine strategy, recommending a stop to administration of AstraZeneca’s Covid shots in Europe to people aged over 60 and younger age groups, amid fears over very rare blood clotting.

“Misinformation is making the rounds today. This is the situation: Benefit/risk balance of AstraZeneca #Covid19 vaccine is positive and it remains authorised for all populations,” the EMA said in a tweet on Sunday.

Cavaleri was also quoted by the newspaper advising the use of the Johnson & Johnson vaccine preferentially for the over-60s.

The European Union has approved AstraZeneca and Johnson & Johnson vaccines for all populations aged 18 and above. However, both viral vector-based jabs have been marred by various reports of rare blood clots.

The EU has also authorised Pfizer-BioNTech and Moderna’s RNA based Covid-19 vaccines.
Asked by the newspaper whether it would be better to stop using AstraZeneca for all age groups, Cavaleri had said: “Yes, and it is an option that many countries, such as France and Germany, are considering in the light of the increased availability of mRNA vaccines.”

“However, incidents were very rare after the first dose. It is true that there is less data on the second dose, but in the United Kingdom it (the vaccination programme) is going well,” he added.

On June 11, Italy restricted the use of AstraZeneca doses to those aged 60 years and above, after a teenager who had received the shot died from a rare form of blood clotting.

In March, the two-dose vaccine was briefly halted by many European countries, including Italy, over concerns about the rare blood clotting problems.

But, its usage was resumed in April, after the EMA said its benefits outweighed any risks.

ALSO READ-Japan approves Moderna, AstraZeneca jabs

READ MORE-EU sues AstraZeneca for contract breach

Previous Story

Afghan forces capture key Taliban commander

Next Story

‘China’s three-child policy won’t prevent lower annual births’

Latest from -Top News

Trump tariffs send world markets into panic

US benchmark crude oil shed $2.70 to $64.25 a barrel after major oil producers announced they plan to increase production. Brent crude, the international standard, was down $2.63 at $67.51 a barrel

EU prepares retaliation for Trump’s tariffs

The European Commission is assembling a fresh round of counter-tariffs aimed at US goods, adding to two existing lists of potential targets—one of which includes products that were hit by suspended tariffs

US, EU slam China’s war games near Taiwan

US President Donald Trump underscored the need to maintain peace in the Taiwan Strait, advocating for a diplomatic approach to cross-strait tensions while warning against the use of force The United States

£13.9 billion of R&D fund to boost innovation, jobs

Funding outlined to support transformational R&D in areas like life sciences, green energy, engineering and beyond More UK innovators like those developing treatment-transforming dementia tests or building world-leading testing facilities to power
Go toTop

Don't Miss

Meta faces new EU complaint over ‘pay for privacy’ consent

The new complaint, filed with the Austrian data protection authority,

Nepal to begin inoculations with Chinese vax

A shipment of the Chinese Covid-19 vaccines developed by Chinese